strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide

Names

[ Name ]:
strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide

[Synonym ]:
1H-Benzimidazole,5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt
(-)-5-Methoxy-2-((S)-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole strontium salt
Esomeprazole strontium anhydrous
1H-Benzimidazole,6-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt (2:1)
Fm0F67 anhydrous
UNII-SCC2RK476A

Biological Activity

[Description]:

Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Endocrinology

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump

[In Vitro]

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) hemistrontium treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1]. Cell Viability Assay[1] Cell Line: MDA-MB-468 cells Concentration: 25 µM, 50 µM, 75 µM, 100 µM Incubation Time: 20 hours Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

[In Vivo]

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] Dosage: 30 mg/kg, 300 mg/kg Administration: Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

[References]

[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

Chemical & Physical Properties

[ Molecular Formula ]:
C₃₄H₃₆N₆O₆S₂Sr

[ Molecular Weight ]:
776.43600

[ Exact Mass ]:
776.11900

[ PSA ]:
186.82000

[ LogP ]:
6.78900

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.